Rusfertide acetate is under clinical development by Protagonist Therapeutics and currently in Phase III for Polycythemia Vera. According to GlobalData, Phase III drugs for Polycythemia Vera have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Rusfertide acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rusfertide acetate overview
PTG-300 is under development for the treatment of iron overload related indications including polycythemia vera and hereditary hemochromatosis. It is a hepcidin mimetic. It is injected through subcutaneous route. The drug candidate is developed based on VectrixTM technology platform.
It was also under development for beta-thalassemia and myelodysplastic syndromes.
Protagonist Therapeutics overview
Protagonist Therapeutics (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist’s peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. Protagonist’ product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and hematological disorders. The company has its operations in the US and Australia. Protagonist is headquartered in Milpitas, California, the US.
For a complete picture of Rusfertide acetate’s drug-specific PTSR and LoA scores, buy the report here.